Shana Krstevska, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Acadia Pharmaceuticals Inc at 27.2% of the total. Reporting peaked in 2022 at $4,119 and has fallen 67.0% since, to $1,361 in 2025.
Across 161 payments — averaging $89.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$4K
- Abbott$4K
- UCB, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- Pacira Pharmaceuticals Incorporated$715
- Ipsen Biopharmaceuticals, Inc$581
- plus $3K from 12 others
Across 26 payments — averaging $3714.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$55K
- Acadia Pharmaceuticals Inc$17K
- Janssen Research & Development, LLC$14K
- UCB SA$11K
What the payments were for
- Consulting fees$3,63725%
- Travel & lodging$4,69533%
- Food & beverage$5,99442%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 8 | $3,897 |
| Abbott | 21 | $3,595 |
| UCB, Inc. | 9 | $1,710 |
| Neurocrine Biosciences, Inc. | 47 | $1,129 |
| Pacira Pharmaceuticals Incorporated | 4 | $715 |
| Ipsen Biopharmaceuticals, Inc | 8 | $581 |
| Boston Scientific | 5 | $416 |
| AstraZeneca | 3 | $385 |
| MDD US Operations, LLC | 24 | $377 |
| Medtronic | 4 | $286 |
| AbbVie | 6 | $270 |
| Amneal Pharmaceuticals LLC | 2 | $255 |
| Novartis | 13 | $237 |
| Kyowa Kirin, Inc. | 2 | $203 |
| Teva Pharmaceuticals USA, Inc. | 1 | $135 |
| Revance Therapeutics, Inc. | 1 | $116 |
| Adamas Pharmaceuticals, Inc. | 2 | $27 |
| Corium, LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$3,637
- INFINITY$2,091
- Infinity DBS Pulse Generators$1,259
- Iovera$683
- DYSPORT$501
- GENERAL DBS$262
- ULTOMIRIS$260
- CREXONT$255
- Austedo XR$135
- SOLIRIS$125
- ONGENTYS$125
- NOURIANZ$122
- VERCISE$120
- DAXXIFY$116
- BOTOX$105
How this compares
$14,344 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 34 | $388,494 |
| AustedoDeutetrabenazine | 19 | $183,486 |
| GocovriAmantadine Hcl | 33 | $108,182 |
| RytaryCarbidopa/Levodopa | 36 | $70,892 |
| NourianzIstradefylline | 21 | $49,549 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 803 | $48,765 |
| Tetrabenazine | 16 | $40,679 |
| Pramipexole ErPramipexole Di-Hcl | 57 | $23,145 |
| Rasagiline Mesylate | 118 | $22,337 |
| Ropinirole ErRopinirole Hcl | 61 | $16,032 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 34 | $13,800 |
| Selegiline Hcl | 45 | $9,918 |
| AmantadineAmantadine Hcl | 121 | $8,213 |
| Entacapone | 32 | $6,699 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 200 | $6,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,129 | $388,49434 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $135 | $183,48619 claims |
| MDD US Operations, LLCGocovri | $377 | $108,18233 claims |
| Amneal Pharmaceuticals LLCRytary | $255 | $70,89236 claims |
| Kyowa Kirin, Inc.Nourianz | $203 | $49,54921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 652 neurology providers in Michigan.
Other neurology in Troy
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Wade CooperAnn Arbor$991K
- Bisena BulicaDetroit$900K
- Julie BurnhamMount Clemens$836K
- Amit MasihOkemos$785K
- Martin BelkinFarmington Hills$712K
- Robert PaceOwosso$693K
- Rosemarie WalchOwosso$563K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.